RT Journal Article
T1 Plasma Chemokines in Patients with Alcohol Use Disorders: Association of CCL11 (Eotaxin-1) with Psychiatric Comorbidity
A1 García-Marchena, Nuria
A1 Araos, Pedro Fernando
A1 Barrios, Vicente
A1 Sánchez-Marín, Laura
A1 Chowen, Julie A
A1 Pedraz, María
A1 Castilla-Ortega, Estela
A1 Romero-Sanchiz, Pablo
A1 Ponce, Guillermo
A1 Gavito, Ana L
A1 Decara, Juan
A1 Silva, Daniel
A1 Torrens, Marta
A1 Argente, Jesús
A1 Rubio, Gabriel
A1 Serrano, Antonia
A1 Rodríguez de Fonseca, Fernando
A1 Pavón, Francisco Javier
K1 Chemokine
K1 Alcohol use disorder
K1 Psychiatric comorbidity
K1 Outpatient setting
K1 PRISM
K1 Eotaxin
K1 Sex
K1 Etanol
K1 Femenino
K1 Voluntarios sanos
K1 Humanos
K1 Hígado
K1 Masculino
K1 Trastornos del humor
K1 Pacientes ambulatorios
K1 Fenotipo
K1 Prevalencia
K1 Psiquiatría
K1 Ratas wistar
K1 Células del estroma
K1 Trastornos relacionados con sustancias
K1 gamma-glutamiltransferasa
K1 Trastornos relacionados con alcohol
K1 Aspartato aminotransferasas
K1 Conducta adictiva
K1 Quimiocina CCL11
K1 Quimiocina CX3CL1
K1 Quimiocina CXCL12
K1 Comorbilidad
AB Recent studies have linked changes in peripheral chemokine concentrations to the presence of both addictive behaviors and psychiatric disorders. The present study further explore this link by analyzing the potential association of psychiatry comorbidity with alterations in the concentrations of circulating plasma chemokine in patients of both sexes diagnosed with alcohol use disorders (AUD). To this end, 85 abstinent subjects with AUD from an outpatient setting and 55 healthy subjects were evaluated for substance and mental disorders. Plasma samples were obtained to quantify chemokine concentrations [C-C motif (CC), C-X-C motif (CXC), and C-X3-C motif (CX3C) chemokines]. Abstinent AUD patients displayed a high prevalence of comorbid mental disorders (72%) and other substance use disorders (45%). Plasma concentrations of chemokines CXCL12/stromal cell-derived factor-1 (p < 0.001) and CX3CL1/fractalkine (p < 0.05) were lower in AUD patients compared to controls, whereas CCL11/eotaxin-1 concentrations were strongly decreased in female AUD patients (p < 0.001). In the alcohol group, CXCL8 concentrations were increased in patients with liver and pancreas diseases and there was a significant correlation to aspartate transaminase (r = +0.456, p < 0.001) and gamma-glutamyltransferase (r = +0.647, p < 0.001). Focusing on comorbid psychiatric disorders, we distinguish between patients with additional mental disorders (N = 61) and other substance use disorders (N = 38). Only CCL11 concentrations were found to be altered in AUD patients diagnosed with mental disorders (p < 0.01) with a strong main effect of sex. Thus, patients with mood disorders (N = 42) and/or anxiety (N = 16) had lower CCL11 concentrations than non-comorbid patients being more evident in women. The alcohol-induced alterations in circulating chemokines were also explored in preclinical models of alcohol use with male Wistar rats. Rats exposed to repeated ethanol (3 g/kg, gavage) had lower CXCL12 (p < 0.01) concentrations and higher CCL11 concentrations (p < 0.001) relative to vehicle-treated rats. Additionally, the increased CCL11 concentrations in rats exposed to ethanol were enhanced by the prior exposure to restraint stress (p < 0.01). Concordantly, acute ethanol exposure induced changes in CXCL12, CX3CL1, and CCL11 in the same direction to repeated exposure. These results clearly indicate a contribution of specific chemokines to the phenotype of AUD and a strong effect of sex, revealing a link of CCL11 to alcohol and anxiety/stress.
PB Frontiers Media
YR 2017
FD 2017-01-18
LK http://hdl.handle.net/10668/2683
UL http://hdl.handle.net/10668/2683
LA en
NO García-Marchena N, Araos PF, Barrios V, Sánchez-Marín L, Chowen JA, Pedraz M, et al. Plasma Chemokines in Patients with Alcohol Use Disorders: Association of CCL11 (Eotaxin-1) with Psychiatric Comorbidity. Front Psychiatry. 2017; 18;7:214.
DS RISalud
RD Apr 18, 2025